AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
AAPL   319.22 (+0.30%)
MSFT   182.18 (+0.43%)
FB   224.87 (-0.26%)
GOOGL   1,428.04 (+0.69%)
AMZN   2,409.91 (+0.26%)
NVDA   345.64 (+1.81%)
CGC   17.77 (-18.11%)
BABA   198.59 (-0.45%)
MU   47.42 (+2.04%)
GE   6.55 (-3.54%)
TSLA   819.99 (+1.76%)
AMD   52.66 (+1.76%)
T   30.55 (-1.64%)
ACB   14.07 (-8.28%)
F   5.64 (-3.75%)
GILD   75.17 (-0.20%)
NFLX   413.65 (+0.05%)
BA   144.40 (-3.62%)
Log in

OTCMKTS:CYTRCytRx Stock Price, Forecast & News

$0.31
-0.40 (-56.34 %)
(As of 05/29/2020 11:28 AM ET)
Add
Compare
Today's Range
$0.31
Now: $0.31
$0.31
50-Day Range
$0.31
MA: $0.43
$0.67
52-Week Range
$0.21
Now: $0.31
$0.85
VolumeN/A
Average Volume91,235 shs
Market Capitalization$24.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Read More
CytRx logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.45 per share

Profitability

Net Income$-7,160,000.00

Miscellaneous

Employees6
Market Cap$24.22 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

CytRx (OTCMKTS:CYTR) Frequently Asked Questions

How has CytRx's stock been impacted by COVID-19 (Coronavirus)?

CytRx's stock was trading at $0.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CYTR shares have increased by 0.0% and is now trading at $0.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CytRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytRx.

When is CytRx's next earnings date?

CytRx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for CytRx.

How were CytRx's earnings last quarter?

CytRx Co. (OTCMKTS:CYTR) released its earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.02. View CytRx's earnings history.

When did CytRx's stock split? How did CytRx's stock split work?

CytRx's stock reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

Has CytRx been receiving favorable news coverage?

Media coverage about CYTR stock has been trending positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CytRx earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutCytRx.

Who are some of CytRx's key competitors?

What other stocks do shareholders of CytRx own?

Who are CytRx's key executives?

CytRx's management team includes the following people:
  • Mr. Steven A. Kriegsman, Chairman & CEO (Age 77)
  • Mr. John Y. Caloz, Chief Financial Officer (Age 67)
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 56)
  • Mr. Eric L. Curtis M.B.A., Pres & COO (Age 50)

What is CytRx's stock symbol?

CytRx trades on the OTCMKTS under the ticker symbol "CYTR."

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $0.31.

How big of a company is CytRx?

CytRx has a market capitalization of $24.22 million and generates $250,000.00 in revenue each year. CytRx employs 6 workers across the globe.

What is CytRx's official website?

The official website for CytRx is www.cytrx.com.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.